THe aim of our study was to evaluate the effects on pruritus and hyperlipoproteinemia and the tolerability of diethylaminoethyl-dextran (DEAE-D), a nonabsorbable, water-soluble bile acid sequestrant resin, in patients with primary biliary cirrhosis (PBC). Thirty patients were randomly allocated to two groups: 15 patients were treated with cholestyramine (8 to 16 gm/day) and 15 with DEAE-D (4 to 6 gm/day) for two months. All patients treated with DEAE-D completed the trial period, whereas four patients on cholestyramine discontinued the drug because of gastrointestinal complaints during the first week. In these patients DEAE-D was then given without any further side effects. Disappearance of pruritus occurred in 45% of patients who completed the treatment with cholestyramine and in 37% with DEAE-D. Both drugs induced a remarkable decrease in hbe semiquantitative measure of intensity of pruritus, serum bile acid concentration, and total cholesterol. No change was observed on high-density lipoprotein cholesterol levels. No other significant differences between treatment groups were observed. We conclude that in PBC DEAE-D is as effective as cholestyramine, but is better tolerated. Therefore, its administration should be considered in the treatment of pruritus and hyperlipidemia in patients with chronic cholestasis.
|Number of pages||7|
|Journal||Current Therapeutic Research|
|Publication status||Published - 1991|
ASJC Scopus subject areas